Abstract
Rapid transmission of coronavirus disease 2019 (COVID-19) was observed in the Shincheonji Church of Jesus, a religious sect in South Korea. The index case was confirmed on February 18, 2020 in Daegu City, and within two weeks, 3,081 connected cases were identified. Doubling times during these initial stages (i.e., February 18 – March 2) of the outbreak were less than 2 days. A stochastic model fitted to the time series of confirmed cases suggests that the basic reproduction number (R0) of COVID-19 was 8.5 [95% credible interval (CrI): 6.3, 10.9] among the church members, whereas (R0 = 1.9 [95% CrI: 0.4, 4.4]) in the rest of the population of Daegu City. The model also suggests that there were already 4 [95% CrI: 2, 11] undetected cases of COVID-19 on February 7 when the index case reportedly presented symptoms. The Shincheonji Church cluster is likely to be emblematic of other outbreak-prone populations where R0 of COVID-19 is higher. Understanding and subsequently limiting the risk of transmission in such high-risk places is key to effective control.
Highlights
Basic reproduction number (R0) of COVID-19 in a religious community of Shincheonji Church of Jesus was estimated to be 8.5 [95% credible interval (CrI): 6.3, 10.9], which is more than 4 times larger than the general population (R0 = 1.9 [95% CrI: 0.4, 4.4])
There were estimated 4 [95% CrI: 2, 11] undetected cases when the index case from the religious community reported symptom on February 7.
The Shincheonji Church cluster is likely to be emblematic of other outbreak-prone populations where R0 of COVID-19 is higher. Understanding and subsequently limiting the risk of transmission in such high-risk places is key to effective control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly supported by Government-wide R&D Fund project for infectious 342 disease research (GFID), Republic of Korea (grant number: HG18C0088) and National Institute for 343 Mathematical Sciences (NIMS) grant funded by the Korean Government (NIMS-B21910000).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses publicly available data and would not require IRB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author affiliations updated; Supplemental files updated.
Data Availability
All of the data referred to in the manuscript is publicly available.
